This recombinant monoclonal antibody is a research-grade biosimilar to Tegoprubart, designed for research targeting CD40 ligand (CD40LG), also known as CD154. CD40LG is a type II transmembrane protein primarily expressed on activated T cells that binds to CD40 on antigen-presenting cells, B cells, and other immune cells. This interaction serves as a critical costimulatory signal for immune activation, regulating B cell proliferation, antibody class switching, germinal center formation, and T cell-dependent immune responses. Dysregulated CD40-CD40LG signaling contributes to autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease, as well as transplant rejection and certain hematologic malignancies.
Tegoprubart is a humanized IgG1 monoclonal antibody that blocks the CD40-CD40LG interaction, currently under clinical investigation for autoimmune conditions and kidney transplant rejection. This biosimilar provides researchers with a valuable tool for investigating CD40LG-mediated immune mechanisms, exploring therapeutic strategies for autoimmune disorders, studying costimulatory pathway blockade, and evaluating immune modulation in transplantation models.
Email: support@cusabio.com
Distributors Worldwide